aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with the mission to develop transformational treatments for repeat expansion disorders (REDs), Triplet Therapeutics focuses on a group of over 50 genetic diseases, including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, and fragile X syndrome. The company leverages advanced biotechnology to address the underlying genetic causes of these conditions, aiming to provide innovative therapeutic solutions that significantly improve patient outcomes.
Triplet Therapeutics has garnered attention through its association with leading experts in genetics and biotechnology. Notable investors include prominent venture capital firms specializing in life sciences. The company has achieved significant milestones in preclinical research and has initiated clinical trials for its lead candidates. Triplet Therapeutics' pioneering approach has the potential to revolutionize treatment paradigms for genetic disorders, making a substantial impact on the lives of affected individuals and their families.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Biotechnology
Technology
Biotech
Model Types
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Triplet Therapeutics founded?
Triplet Therapeutics was founded in 2019.
Where is Triplet Therapeutics’s headquarters located?
Triplet Therapeutics’s headquarters is located in Cambridge, MA, US.
When was Triplet Therapeutics’s last funding round?
Triplet Therapeutics’s most recent funding round was for $49M (USD) in December 2019.
How many employees does Triplet Therapeutics have?
Triplet Therapeutics has 36 employees as of Feb 4, 2024.
How much has Triplet Therapeutics raised to-date?
As of July 05, 2023, Triplet Therapeutics has raised a total of $59M (USD) since Dec 17, 2019.
Add Comparison
Total Raised to Date
$59M
USD
Last Update Dec 17, 2019
Last Deal Details
$49M
USD
Dec 17, 2019
Series A
Total Employees Over Time
36
As of Feb 2024
Triplet Therapeutics Address
Cambridge,
Massachusetts
02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts